Bayer's Pharma Math Gets a New Benchmark as Berenberg Lifts Target to EUR 62
Published on 11/19/2026 at 09:41 | Editorial boerse-global.deBerenberg has raised its price target on Bayer from EUR 53.50 to EUR 62.00 while keeping a "Hold" rating, a move that lands as the market weighs how much of the drugmaker's recent run is already baked into the share price. Analyst Sebastian Bray attributed part of the stock's relative strength to rotation out of technology names and into healthcare and defensive plays, alongside momentum in the pharmaceutical business and progress in US glyphosate litigation.
The shares slipped 0.5% yesterday, a modest pullback against a backdrop that has seen the stock climb 29% over 30 days. That rally is precisely why the distinction between a more optimistic forecast and actual segment performance matters more than whether the advance extends in the near term.
A EUR 5 Billion Yardstick for 2027
According to media reports, Berenberg now models EUR 5 billion in EBITDA for the pharma division in 2027, against a consensus of EUR 4.8 billion. The figure is neither a company target nor a result already achieved — it is a marker for what the more bullish case requires: the segment would have to outperform the consensus estimate to vindicate it.
Bayer gave some support to that thesis with its third-quarter 2026 report, in which it raised the full-year margin outlook for the pharmaceutical division. A higher margin points the direction for profitability, but the following year's EBITDA estimate demands something more — a statement about the absolute size of earnings. Better margins alone do not settle that question.
Approvals Build the Case, but Only If They Reach the P&L
Late last week, the US Food and Drug Administration cleared Asundexian, marketed as Sunharbo, for use alongside an antiplatelet therapy to lower the risk of further strokes in adults who have suffered a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack. Bayer described it as the world's first approved factor XIa inhibitor. Earlier in November, China's NMPA approved Sevabertinib as a first-line treatment for adults with HER2-mutant non-small cell lung cancer. The two decisions cover different markets and patient populations.
Should investors sell immediately? Or is it worth buying Bayer?
In the favorable scenario, those clearances contribute not just to revenue but to the division's bottom line. They count as confirmation of the earnings thesis only once a visible economic contribution emerges — and if profitability improves at the same time, the higher EBITDA expectation gains real weight.
What Would Break the Bull Case
The bearish counterpoint does not require any setback on the approval front. Even with rising sales, the pharma unit could miss the more optimistic estimate if the additional revenue converts too weakly into profit. The improvement could also surface more slowly than a next-year forecast presupposes. In either case, the approvals would remain genuine progress without yet justifying the loftier earnings assumption.
A favorable turn in the US glyphosate proceedings would not offset weaker pharma performance when it comes to testing the segment forecast, either. It could support the investment case for Bayer shares, but it would not evidence greater earning power in the drugs business. Separating the two factors makes it easier to judge which part of the thesis is carrying its weight.
The Numbers That Come Next
The next concrete checkpoint is Bayer's forthcoming reporting on the pharmaceutical division. The point is not to extrapolate a full year from a single quarter, but to see whether the expected improvement is already visible in margin and operating profit. Disclosure on the newly approved medicines could help frame that progress.
As long as earnings and margin move in the same favorable direction, the higher pharma estimate gains plausibility. If segment profit fails to improve despite higher sales, the optimistic scenario loses ground. The hurdle for Bayer, then, is not another positive headline in itself but proof that commercial progress translates into profit for the pharmaceutical arm.
A Spinoff Waiting in the Wings
Bray also flagged a possible later separation of Monsanto, including an initial public offering. Toward the end of the decade, Bayer could, in his assessment, channel the proceeds into pharmaceutical development. For the third quarter of 2026, Bayer reported revenue of EUR 10.1 billion and EBITDA before special items of EUR 1.62 billion, while lifting its outlook for the pharma margin, group EBITDA before special items and free cash flow.
Ad
Bayer Stock: New Analysis - 19 November
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
